122 related articles for article (PubMed ID: 20582983)
21. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
[TBL] [Abstract][Full Text] [Related]
22. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
23. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
Shirakata T; Oka Y; Nishida S; Hosen N; Tsuboi A; Oji Y; Murao A; Tanaka H; Nakatsuka S; Inohara H; Sugiyama H
Anticancer Res; 2012 Mar; 32(3):1081-5. PubMed ID: 22399636
[TBL] [Abstract][Full Text] [Related]
24. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M; Hiraki A; Azuma T; Tsuboi A; Oka Y; Sugiyama H; Fujita S; Tanimoto M; Harada M; Yasukawa M
Clin Cancer Res; 2002 Aug; 8(8):2626-31. PubMed ID: 12171894
[TBL] [Abstract][Full Text] [Related]
25. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
26. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
Ariyaratana S; Loeb DM
Expert Rev Mol Med; 2007 May; 9(14):1-17. PubMed ID: 17524167
[TBL] [Abstract][Full Text] [Related]
27. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S; Kyo S; Myojo S; Dohi S; Ishizaki J; Miyamoto K; Morita S; Sakamoto J; Enomoto T; Kimura T; Oka Y; Tsuboi A; Sugiyama H; Inoue M
Anticancer Res; 2009 Nov; 29(11):4779-84. PubMed ID: 20032435
[TBL] [Abstract][Full Text] [Related]
28. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S; Ohno S; Ohno Y; Takakura M; Kyo S; Soma G; Sugiyama H; Inoue M
Anticancer Res; 2011 Jul; 31(7):2441-5. PubMed ID: 21873157
[TBL] [Abstract][Full Text] [Related]
29. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
Oji Y; Oka Y; Nishida S; Tsuboi A; Kawakami M; Shirakata T; Takahashi K; Murao A; Nakajima H; Narita M; Takahashi M; Morita S; Sakamoto J; Tanaka T; Kawase I; Hosen N; Sugiyama H
Eur J Haematol; 2010 Oct; 85(4):358-60. PubMed ID: 20633041
[TBL] [Abstract][Full Text] [Related]
30. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
31. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
Chiba Y; Hashimoto N; Tsuboi A; Rabo C; Oka Y; Kinoshita M; Kagawa N; Oji Y; Sugiyama H; Yoshimine T
Brain Tumor Pathol; 2010 Apr; 27(1):29-34. PubMed ID: 20425045
[TBL] [Abstract][Full Text] [Related]
33. Cancer immunotherapy targeting WT1 protein.
Sugiyama H
Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010
[TBL] [Abstract][Full Text] [Related]
34. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Tanaka-Harada Y; Hosen N; Nishida S; Shirakata T; Nakajima H; Tatsumi N; Hashimoto N; Taguchi T; Ueda S; Nonomura N; Takeda Y; Ito T; Myoui A; Izumoto S; Maruno M; Yoshimine T; Noguchi S; Okuyama A; Kawase I; Oji Y; Sugiyama H
Anticancer Res; 2010 Jun; 30(6):2247-54. PubMed ID: 20651376
[TBL] [Abstract][Full Text] [Related]
35. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A; Oka Y; Udaka K; Murakami M; Masuda T; Nakano A; Nakajima H; Yasukawa M; Hiraki A; Oji Y; Kawakami M; Hosen N; Fujioka T; Wu F; Taniguchi Y; Nishida S; Asada M; Ogawa H; Kawase I; Sugiyama H
Cancer Immunol Immunother; 2002 Dec; 51(11-12):614-20. PubMed ID: 12439606
[TBL] [Abstract][Full Text] [Related]
36. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors.
Hirabayashi K; Yanagisawa R; Saito S; Higuchi Y; Koya T; Sano K; Koido S; Okamoto M; Sugiyama H; Nakazawa Y; Shimodaira S
Anticancer Res; 2018 Apr; 38(4):2227-2234. PubMed ID: 29599343
[TBL] [Abstract][Full Text] [Related]
38. The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone.
Ikeda K; Shichishima T; Yasukawa M; Nakamura-Shichishima A; Noji H; Akutsu K; Osumi K; Maruyama Y
Exp Hematol; 2007 Apr; 35(4):618-26. PubMed ID: 17379072
[TBL] [Abstract][Full Text] [Related]
39. High-grade astrocytomas show increased Nestin and Wilms's tumor gene (WT1) protein expression.
Rushing EJ; Sandberg GD; Horkayne-Szakaly I
Int J Surg Pathol; 2010 Aug; 18(4):255-9. PubMed ID: 19578047
[TBL] [Abstract][Full Text] [Related]
40. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
